Max-Dohrn-Strasse 8-10
Berlin 10589
Germany
49 30 726247 0
https://www.noxxon.com
Sector(s):Â Healthcare
Industry:Â Biotechnology
Full Time Employees:Â 13
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Aram Mangasarian Ph.D. | CEO & Member of Management Board | 488.62k | N/A | 1970 |
Mr. Bryan Jennings | CFO & Member of Management Board | N/A | N/A | N/A |
Dr. Jarl Ulf Jungnelius M.D., Ph.D. | Sr. Medical Advisor, Chief Medical Officer & Member of Management Board | N/A | N/A | 1951 |
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
NOXXON Pharma N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.